Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study

被引:19
|
作者
Choi, Peter [1 ]
Farouk, Mourad [2 ]
Manamley, Nick [3 ]
Addison, Janet [3 ]
机构
[1] John Hunter Hosp, Dept Nephrol, New Lambton Hts, NSW 2305, Australia
[2] Amgen Europe GmbH, CH-6301 Zug, Switzerland
[3] Amgen UK Ltd, Cambridge, England
关键词
Anemia; Chronic kidney disease; Darbepoetin alfa; Dose conversion; Erythropoiesis-stimulating agent; Hematology; Hemodialysis; Medication switching; Pegylated erythropoietin beta; Retrospective study; ANEMIA; AGENTS;
D O I
10.1007/s12325-013-0063-y
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
There is limited information published on switching erythropoiesis-stimulating agent (ESA) treatment for anemia associated with chronic kidney disease (CKD) from darbepoetin alfa (DA) to methoxy polyethylene glycol-epoetin beta (PEG-Epo) outside the protocol of interventional clinical studies. AFFIRM (Aranesp Efficiency Relative to Mircera) was a retrospective, multi-site, observational study designed to estimate the population mean maintenance dose conversion ratio [DCR; dose ratio achieving comparable hemoglobin level (Hb) between two evaluation periods] in European hemodialysis patients whose treatment was switched from DA to PEG-Epo. Eligible patients had received hemodialysis for a parts per thousand yen12 months and DA for a parts per thousand yen7 months. Data were collected from 7 months before until 7 months after switching treatment. DCR was calculated for patients with Hb and ESA data available in both evaluation periods (EP; Months 1 and 2 were defined as the pre-switch EP, and Months 6 and 7 as the post-switch EP). Red blood cell transfusions pre- and post-switch were quantified. Of 302 patients enrolled, 206 had data available for DCR analysis. The geometric mean DCR was 1.17 (95% CI 1.05, 1.29). Regression analysis indicated a non-linear relationship between pre- and post-switch ESA doses; DCR decreased with increasing pre-switch DA dose. The geometric mean weekly ESA doses were 24.1 mu g DA in the pre-switch EP and 28.6 mu g PEG-Epo in the post-switch EP. Mean Hb was 11.5 g/dL in the pre-switch EP and 11.4 g/dL in the post-switch EP. There were 16 transfusions and 34 units transfused in the pre-switch period, versus 48 transfusions and 95 units transfused post-switch. Excluding patients receiving a transfusion within 90 days of or during either EP, the DCR was 1.21 (95% CI 1.09, 1.35). In these hemodialysis patients switched from DA to PEG-Epo the DCR was 1.17 and 1.21 after accounting for the effect of transfusions. The number of transfusions and units transfused increased approximately threefold from the pre-switch to the post-switch period.
引用
收藏
页码:1007 / 1017
页数:11
相关论文
共 25 条
  • [1] Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study
    Peter Choi
    Mourad Farouk
    Nick Manamley
    Janet Addison
    Advances in Therapy, 2013, 30 : 1007 - 1017
  • [2] Preservation of Anemia Control and Weekly ESA Dosage After Conversion from PEG-Epoetin Beta to Darbepoetin Alfa in Adult Hemodialysis Patients: The TRANSFORM Study
    Donck, Jan
    Gonzalez-Tabares, Lourdes
    Chanliau, Jacques
    Martin, Heike
    Stamatelou, Kyriaki
    Manamley, Nick
    Farouk, Mourad
    Addison, Janet
    ADVANCES IN THERAPY, 2014, 31 (11) : 1155 - 1168
  • [3] Preservation of Anemia Control and Weekly ESA Dosage After Conversion from PEG-Epoetin Beta to Darbepoetin Alfa in Adult Hemodialysis Patients: The TRANSFORM Study
    Jan Donck
    Lourdes Gonzalez-Tabares
    Jacques Chanliau
    Heike Martin
    Kyriaki Stamatelou
    Nick Manamley
    Mourad Farouk
    Janet Addison
    Advances in Therapy, 2014, 31 : 1155 - 1168
  • [4] Switch From Epoetin Beta to Darbepoetin Alfa Treatment of Anemia in Taiwanese Hemodialysis Patients: Dose Equivalence by Hemoglobin Stratification
    Liao, Shang-Chih
    Hung, Cheng-Chieh
    Lee, Chien-Te
    Lee, Chih-Hsiung
    Lee, Chin-Chan
    Lin, Chun-Liang
    Sun, Chiao-Yin
    Cheng, Ben-Chung
    Yang, Chih-Chao
    Wu, Chien-Hsing
    Chen, Jin-Bor
    THERAPEUTIC APHERESIS AND DIALYSIS, 2016, 20 (04) : 400 - 407
  • [5] Resistance index to epoetin alfa and to darbepoetin alfa in chronic hemodialysis patients:: A cohort study
    Perez-Garcia, R.
    Benitez, P. Rodriguez
    Jofre, R.
    Lopez-Gomez, J. M.
    Villaverde, M. T.
    Blanco, A.
    Blanco, S.
    Sanchez, M.
    NEFROLOGIA, 2007, 27 (03): : 340 - 349
  • [6] Anemia Management With Darbepoetin-Alfa in Outpatient Hemodialysis Patients Switched From Epoetin-Alfa: A Community Hospital Experience
    Agrawal, Varun
    Mukherjee, Sudipto
    Kosuri, Rajani
    Dumler, Francis
    AMERICAN JOURNAL OF THERAPEUTICS, 2010, 17 (05) : 469 - 475
  • [7] Clinical outcomes associated with conversion from epoetin alfa to darbepoetin alfa in hospitalized hemodialysis patients
    Sarac, Erdal
    Chikyarappa, Anand
    Sabol, Brian
    Gemmel, David
    Globe, Denise
    Barlev, Arie
    Audhya, Paul
    AMERICAN JOURNAL OF NEPHROLOGY, 2006, 26 (06) : 571 - 578
  • [8] Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability
    Arrieta, Javier
    Moina, Inigo
    Molina, Jose
    Gallardo, Isabel
    Muniz, Maria Luisa
    Robledo, C. Armen
    Garcia, Oscar
    Vidaur, Fernando
    Muoz, Rosa Ines
    Iribar, Izaskun
    Aguirre, Roman
    Maza, Antonio
    INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE, 2014, 7 : 353 - 359
  • [9] Effects of darbepoetin alfa and epoetin beta pegol on iron kinetics in hemodialysis patients
    Sawa J.
    Inaba M.
    Noguchi K.
    Nakagawa C.
    Kuwamura M.
    Kuwamura Y.
    Wada N.
    Kitatani K.
    Kawaguchi Y.
    Kumeda Y.
    Renal Replacement Therapy, 2 (1)
  • [10] Comparative Efficacy and Safety Study of Darbepoetin Alfa versus Epoetin Alfa in Management of Anemia Associated with ESRD in Egyptian Hemodialysis Patients
    El-Ashmawy, Nahla E.
    Khedr, Eman G.
    Kotb, Nahla S.
    Salem, Fathi
    Ibrahim, Amera O.
    CURRENT DRUG SAFETY, 2022, 17 (03) : 250 - 258